Note

Aspire Pharma initiated and funded this article but had no input into the content and were able to review in advance of publication for factual accuracy and compliance checks only. 

Medicines Optimisation Centricity

Aspire Pharma initiated and funded a series of workshops run and facilitated by HSJ (previously Wilmington Healthcare). The workshops brought together key NHS and Pharmacy stakeholders to debate and discuss three themes:

Workshop Series One Workshop Series One

Workshop Series One

Held in March 2023

This series explored the practicalities of medicine optimisation, sharing best practices to determine “the way forward” to ensuring optimal medicine optimisation.

Learn more about the findings of workshop series 1 and read the ‘Medicines Optimisation Centricity: The way forward’ white paper:

Workshop Series Two Workshop Series Two

Workshop Series Two

Held in July 2024

This workshop explored whether medicines optimisation could be creating health inequalities/inequities. The roundtable offered a chance to reflect on medicines optimisation within the new integrated care landscape. It examined whether it truly achieves its intended goals, or if the current approach actually exacerbates inequalities and negatively impact specific groups within our population.

Learn more about the findings of workshop series 2 and read the ‘Medicines Optimisation Centricity: Is it creating health inequalities?’ white paper:

Workshop Series Three Workshop Series Three

Workshop Series Three

Held in June 2025

This roundtable event, brought together key pharmacy stakeholders to debate and discuss the value of medicines in the patient pathway. Of particular focus was understanding patient centric access to medicines and how to ensure that services are delivered with patients in mind.

Learn more about the findings of workshop series 3 and read the ‘Medicines Optimisation Centricity: What is the value of medicines in the patient pathway?’ white paper:

MOC1010347G2_OCT2025

© Copyright HSJ in partnership with Aspire Pharma Limited